You just read:

BerGenBio Completes Recruitment Into Second Stage of Phase II Trial With Selective AXL inhibitor bemcentinib in Combination with KEYTRUDA® in Patients With Advanced NSCLC

News provided by

BerGenBio ASA

08 May, 2019, 11:46 BST